Loan & DebtJul 20, 2026, 07:01 PM
Quantum BioPharma to Settle CAD$123.5K Debt via Share Issuance
AI Summary
Quantum BioPharma Ltd. announced its board of directors approved the settlement of CAD$123,487.43 owed to arm’s length creditors and insiders. This debt will be settled through the issuance of Class B subordinate voting shares at a deemed price based on the lower of CAD$4.26 or the closing price on the Canadian Securities Exchange. The company is a biopharmaceutical firm developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, and also holds a 19.84% stake in Unbuzzd Wellness Inc., receiving royalties from its sales.
Key Highlights
- Board approved settlement of CAD$123,487.43 debt.
- Debt to be settled by issuing Class B subordinate voting shares.
- Deemed share price is the lower of CAD$4.26 or CSE closing price.
- Shares issued to both arm's length creditors and insiders.
- Securities are not registered under the U.S. Securities Act.
- Company focuses on neurodegenerative, metabolic, and alcohol misuse disorders.
- Retains 19.84% ownership in Unbuzzd Wellness Inc. as of March 31, 2026.
- Receives 7% royalty on unbuzzd™ sales until $250 million, then 3% in perpetuity.
Price Impact
More from QNTM